Flonase Allergy Relief Exclusivity Sliced Up By Label Carve-Out
This article was originally published in The Tan Sheet
FDA grants Glaxo market exclusivity for OTC as the first OTC fluticasone product, but with a label carve-out that limits exclusivity to the indication of “OTC use for temporary relief of ocular symptoms due to hay fever or other upper respiratory allergies.”
You may also be interested in...
Nasonex 24HR Allergy also will be first OTC mometasone furoate product available in US. It will compete in OTC intranasal corticosteroids category already led by other brands switched from Rx to nonprescription over past eight years.
Bayer launches multi-year campaign “Outsideologist Project” for Claritin to offer parents fun ways to get their children outside. GSK’s “Change the Game” campaign for Flonase as official allergy relief partner of MLB has new spokesman.
CHPA says growing use of allergy OTCs from 2009 through 2015 in the US is a sign of more consumers prioritizing self-care over using health care services, but allergy specialists say their patients often have to start with an OTC even when they have a prescription.